Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation

Breast Cancer Research

Volumn 10, Issue 6, 2008, Pages

  Perotti, Christian ^a   Liu, Ruixuan ^a   Parusel, Christine T ^b   Böcher, Nadine ^b   Schultz, Jörg ^c   Bork, Peer ^c   Pfitzner, Edith ^b   Groner, Bernd ^b   Shemanko, Carrie S ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 90; HSP90ALPHA PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; LUCIFERASE; MACROCYCLIC LACTAM; MESSENGER RNA; PROLACTIN; PROTEIN P53; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN; TANESPIMYCIN;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL DIFFERENTIATION; DRUG EFFECT; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NORTHERN BLOTTING; NUCLEIC ACID HYBRIDIZATION; PHYSIOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BENZOQUINONES; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; JANUS KINASE 2; LACTAMS, MACROCYCLIC; LUCIFERASES; NUCLEIC ACID HYBRIDIZATION; PROLACTIN; RNA, MESSENGER; STAT5 TRANSCRIPTION FACTOR; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63849316576     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2193     Document Type: Article

References (99)

1. Shemanko CS, Groner B. Transcription factors, cofactors and target genes mediating prolactin action. Prolactin 2001, 381-404. USA: Kluwer Academic Publishers, Horseman ND.
2. Watson CJ. Involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ. Breast Cancer Res 2006, 8:203. 1557708, 16677411, 10.1186/bcr1401.
3. Clarkson RW, Boland MP, Kritikou EA, Lee JM, Freeman TC, Tiffen PG, Watson CJ. The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 2006, 20:675-685. 10.1210/me.2005-0392, 16293640.
4. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004, 64:6814-6819. 10.1158/0008-5472.CAN-04-1870, 15375001.
5. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006, 66:1824-1832. 10.1158/0008-5472.CAN-05-2292, 16452244.
6. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003, 24:1-27. 1698952, 12588805, 10.1210/er.2001-0036.
7. Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: An epidemiologic perspective. J Mammary Gland Biol Neoplasia 2008, 13:41-53. 10.1007/s10911-008-9063-y, 18246319.
8. Arendt LM, Rose-Hellekant TA, Sandgren EP, Schuler LA. Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice. Am J Pathol 2006, 168:1365-1374. 1606572, 16565509, 10.2353/ajpath.2006.050861.
9. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 2003, 22:4664-4674. 1630768, 12879011, 10.1038/sj.onc.1206619.
10. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997, 100:2744-2751. 508478, 9389738, 10.1172/JCI119820.
11. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 2000, 19:1077-1084. 10.1038/sj.onc.1203348, 10713693.
12. Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE, Ormandy CJ. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 2007, 26:543-553. 10.1038/sj.onc.1209838, 16862169.
13. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007, 25:1482-1488. 10.1200/JCO.2006.07.6356, 17372279.
14. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. 1635162, 15068665.
15. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R, Loriod B, Giaconia A, Benziane A, Devilard E, Jacquemier J, Viens P, Nguyen C, Birnbaum D, Houlgatte R. Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002, 11:863-872. 10.1093/hmg/11.8.863, 11971868.
16. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004, 8:409-422. 10.1517/14728222.8.5.409, 15469392.
17. Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008, 13:93-103. 10.1007/s10911-008-9062-z, 18228120.
18. Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, Dey SK, Dotto GP, Weinberg RA, Jan T. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002, 3:877-887. 10.1016/S1534-5807(02)00365-9, 12479812.
19. Gass S, Harris J, Ormandy C, Brisken C. Using gene expression arrays to elucidate transcriptional profiles underlying prolactin function. J Mammary Gland Biol Neoplasia 2003, 8:269-285. 10.1023/B:JOMG.0000010029.85796.63, 14973373.
20. Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, Hilton HN, Wittlin S, Alexander WS, Lindeman GJ, Visvader JE, Ormandy CJ. Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol 2006, 20:1177-1187. 10.1210/me.2005-0473, 16469767.
21. Hou Z, Bailey JP, Vomachka AJ, Matsuda M, Lockefeer JA, Horseman ND. Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is induced by prolactin and suppressed by progesterone in mammary epithelium. Endocrinology 2000, 141:4278-4283. 10.1210/en.141.11.4278, 11089563.
22. Naylor MJ, Ginsburg E, Iismaa TP, Vonderhaar BK, Wynick D, Ormandy CJ. The neuropeptide galanin augments lobuloalveolar development. J Biol Chem 2003, 278:29145-29152. 10.1074/jbc.M303746200, 12759342.
23. Naylor MJ, Oakes SR, Gardiner-Garden M, Harris J, Blazek K, Ho TW, Li FC, Wynick D, Walker AM, Ormandy CJ. Transcriptional changes underlying the secretory activation phase of mammary gland development. Mol Endocrinol 2005, 19:1868-1883. 10.1210/me.2004-0254, 15705664.
24. Ormandy CJ, Naylor M, Harris J, Robertson F, Horseman ND, Lindeman GJ, Visvader J, Kelly PA. Investigation of the transcriptional changes underlying functional defects in the mammary glands of prolactin receptor knockout mice. Recent Prog Horm Res 2003, 58:297-323. 10.1210/rp.58.1.297, 12795425.
25. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007, 32:517-530. 10.1007/s12038-007-0051-y, 17536171.
26. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216. 10.1196/annals.1391.012, 17513464.
27. Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004, 15:651-662. 10.1097/01.cad.0000136876.11928.be, 15269596.
28. Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol 2006, 33:457-465. 10.1053/j.seminoncol.2006.04.001, 16890800.
29. Workman P, Maloney A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002, 2:3-24. 10.1517/14712598.2.1.3, 11772336.
30. Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 2002, 417:618-624. 10.1038/nature749, 12050657.
31. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998, 396:336-342. 10.1038/24550, 9845070.
32. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004, 6:507-514. 10.1038/ncb1131, 15146192.
33. Teng SC, Chen YY, Su YN, Chou PC, Chiang YC, Tseng SF, Wu KJ. Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J Biol Chem 2004, 279:14649-14655. 10.1074/jbc.M308842200, 14724288.
34. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998, 79:129-168. 10.1016/S0163-7258(98)00013-8, 9749880.
35. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007, 67:2932-2937. 10.1158/0008-5472.CAN-06-4511, 17409397.
36. Yano M, Naito Z, Tanaka S, Asano G. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 1996, 87:908-915.
37. Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 1999, 137:45-51. 10.1016/S0304-3835(98)00338-3, 10376793.
38. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410. 10.1038/nature01913, 14508491.
39. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13(Suppl 1):S125-135. 10.1677/erc.1.01324, 17259553.
40. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007, 25:5410-5417. 10.1200/JCO.2007.11.7960, 18048823.
41. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006, 95:323-348. 10.1016/S0065-230X(06)95009-X, 16860662.
42. Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 2005, 24:1648-1652. 10.1038/sj.onc.1208345, 15674342.
43. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995, 92:8831-8835. 41061, 7568026, 10.1073/pnas.92.19.8831.
44. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. Embo J 1994, 13:2182-2191. 395072, 7514531.
45. Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B. Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. Embo J 1988, 7:2089-2095. 454494, 3416834.
46. Uchida K, Yoshimura A, Inazawa J, Yanagisawa K, Osada H, Masuda A, Saito T, Takahashi T, Miyajima A. Molecular cloning of CISH, chromosome assignment to 3p21.3, and analysis of expression in fetal and adult tissues. Cytogenet Cell Genet 1997, 78:209-212. 10.1159/000134658, 9465889.
47. Wakao H, Schmitt-Ney M, Groner B. Mammary gland-specific nuclear factor is present in lactating rodent and bovine mammary tissue and composed of a single polypeptide of 89 kDa. J Biol Chem 1992, 267:16365-16370.
48. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. Embo J 1994, 13:4361-4369. 395363, 7925280.
49. Shaw-Bruha CM, Pirrucello SJ, Shull JD. Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing. Breast Cancer Res Treat 1997, 44:243-253. 10.1023/A:1005879103367, 9266104.
50. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J 1995, 14:2816-2826. 398400, 7796808.
51. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997, 89:3148-3154.
52. Verdier F, Rabionet R, Gouilleux F, Beisenherz-Huss C, Varlet P, Muller O, Mayeux P, Lacombe C, Gisselbrecht S, Chretien S. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B. Mol Cell Biol 1998, 18:5852-5860. 109171, 9742102.
53. Bole-Feysot C, Perret E, Roustan P, Bouchard B, Kelly PA. Analysis of prolactin-modulated gene expression profiles during the Nb2 cell cycle using differential screening techniques. Genome Biol 2000, 1:RESEARCH0008. 11178248, 138841, 10.1186/gb-2000-1-4-research0008.
54. Djiane J, Houdebine LM, Kelly PA. Correlation between prolactin-receptor interaction, down-regulation of receptors, and stimulation of casein and deoxyribonucleic acid biosynthesis in rabbit mammary gland explants. Endocrinology 1982, 110:791-795.
55. Desrivières S, Prinz T, Castro-Palomino Laria N, Meyer M, Boehm G, Bauer U, Schäfer J, Neumann T, Groner B, Shemanko CS. Comparative proteomic analysis of proliferating and functionally differentiated mammary epithelial cells. Molecular and Cellular Proteomics 2003, 2:1039-1054. 12885951, 10.1074/mcp.M300032-MCP200.
56. Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 1997, 17:121-134.
57. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003, 197:157-168. 10.1002/jcp.10364, 14502555.
58. Weaver AM, Silva CM. Modulation of signal transducer and activator of transcription 5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain. Mol Endocrinol 2006, 20:2392-2405. 10.1210/me.2005-0418, 16772534.
59. Abdelmagid SA, Too CK. Prolactin and Estrogen Upregulate Carboxypeptidase-D to Promote Nitric Oxide Production and Survival of MCF-7 Breast Cancer Cells. Endocrinology 2008,
60. Chakravarti P, Henry MK, Quelle FW. Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells. Int J Oncol 2005, 26:509-514.
61. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 1999, 5:3583-3593.
62. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995, 55:2591-2595.
63. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004, 91:305-311.
64. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW, Hennighausen L. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 2004, 24:8037-8047. 515028, 15340066, 10.1128/MCB.24.18.8037-8047.2004.
65. Iavnilovitch E, Eilon T, Groner B, Barash I. Expression of a carboxy terminally truncated Stat5 with no transactivation domain in the mammary glands of transgenic mice inhibits cell proliferation during pregnancy, delays onset of milk secretion, and induces apoptosis upon involution. Mol Reprod Dev 2006, 73:841-849. 10.1002/mrd.20479, 16596634.
66. Merlo GR, Basolo F, Fiore L, Duboc L, Hynes NE. p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Biol 1995, 128:1185-1196. 2120420, 7896881, 10.1083/jcb.128.6.1185.
67. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000, 275:9390-9395. 10.1074/jbc.275.13.9390, 10734083.
68. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 2002, 62:3132-3137.
69. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003, 63:2139-2144.
70. Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J, Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 2006, 104:146-155. 10.1016/j.imlet.2005.11.018, 16384610.
71. Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C, Murray GI. Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol 2006, 210:351-357. 10.1002/path.2056, 16981251.
72. Poetsch M, Dittberner T, Cowell JK, Woenckhaus C. TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin. Oncogene 2000, 19:5817-5820. 10.1038/sj.onc.1203961, 11126369.
73. Grzmil M, Thelen P, Hemmerlein B, Schweyer S, Voigt S, Mury D, Burfeind P. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am J Pathol 2003, 163:543-552. 1868227, 12875974.
74. Brooks C, Wei Q, Feng L, Dong G, Tao Y, Mei L, Xie ZJ, Dong Z. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci USA 2007, 104:11649-11654. 1913853, 17606912, 10.1073/pnas.0703976104.
75. Neuspiel M, Zunino R, Gangaraju S, Rippstein P, McBride H. Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization. J Biol Chem 2005, 280:25060-25070. 10.1074/jbc.M501599200, 15878861.
76. Patry C, Bouchard L, Labrecque P, Gendron D, Lemieux B, Toutant J, Lapointe E, Wellinger R, Chabot B. Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res 2003, 63:7679-7688.
77. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study. Proteomics 2006, 6:1681-1694. 10.1002/pmic.200500417, 16456880.
78. Radhika V, Onesime D, Ha JH, Dhanasekaran N. Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1. J Biol Chem 2004, 279:49406-49413. 10.1074/jbc.M408836200, 15339924.
79. Ramsay AG, Keppler MD, Jazayeri M, Thomas GJ, Parsons M, Violette S, Weinreb P, Hart IR, Marshall JF. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res 2007, 67:5275-5284. 10.1158/0008-5472.CAN-07-0318, 17545607.
80. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772. 10.1038/nrc1716, 16175177.
81. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004, 206:149-157. 10.1016/j.canlet.2003.08.032, 15013520.
82. Merlo GR, Graus-Porta D, Cella N, Marte BM, Taverna D, Hynes NE. Growth, differentiation and survival of HC11 mammary epithelial cells: diverse effects of receptor tyrosine kinase-activating peptide growth factors. Eur J Cell Biol 1996, 70:97-105.
83. Wu W, Zou M, Brickley DR, Pew T, Conzen SD. Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol Endocrinol 2006, 20:2304-2314. 10.1210/me.2006-0131, 16690749.
84. Schorr K, Furth PA. Induction of bcl-xL expression in mammary epithelial cells is glucocorticoid-dependent but not signal transducer and activator of transcription 5-dependent. Cancer Res 2000, 60:5950-5953.
85. al-Sakkaf KA, Dobson PR, Brown BL. Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells. J Mol Endocrinol 1997, 19:347-350. 10.1677/jme.0.0190347, 9460655.
86. Bailey JP, Nieport KM, Herbst MP, Srivastava S, Serra RA, Horseman ND. Prolactin and transforming growth factor-beta signaling exert opposing effects on mammary gland morphogenesis, involution, and the Akt-forkhead pathway. Mol Endocrinol 2004, 18:1171-1184. 10.1210/me.2003-0345, 14963111.
87. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001, 21:2203-2212. 86854, 11238953, 10.1128/MCB.21.6.2203-2212.2001.
88. Schwertfeger KL, Richert MM, Anderson SM. Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 2001, 15:867-881. 10.1210/me.15.6.867, 11376107.
89. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002, 277:39858-39866. 10.1074/jbc.M206322200, 12176997.
90. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000, 97:10832-10837. 27109, 10995457, 10.1073/pnas.170276797.
91. Galea-Lauri J, Richardson AJ, Latchman DS, Katz DR. Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide: a possible role in immunopathology. J Immunol 1996, 157:4109-4118.
92. Sapozhnikov AM, Ponomarev ED, Tarasenko TN, Telford WG. Spontaneous apoptosis and expression of cell surface heat-shock proteins in cultured EL-4 lymphoma cells. Cell Prolif 1999, 32:363-378. 10.1111/j.1365-2184.1999.tb01354.x, 10646688.
93. Wu YP, Kita K, Suzuki N. Involvement of human heat shock protein 90 alpha in nicotine-induced apoptosis. Int J Cancer 2002, 100:37-42. 10.1002/ijc.10449, 12115584.
94. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998, 18:1517-1524. 108866, 9488468.
95. Merlo GR, Venesio T, Taverna D, Marte BM, Callahan R, Hynes NE. Growth suppression of normal mammary epithelial cells by wild-type p53. Oncogene 1994, 9:443-453.
96. Blagosklonny MV, Wu GS, Somasundaram K, E S, W D. Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells. International Journal of Oncology 1997, 11:1165-1170.
97. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21:1159-1166. 10.1038/sj.onc.1205184, 11850835.
98. Wang K, Ma Q, Ren Y, He J, Zhang Y, Zhang Y, Chen W. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol Rep 2007, 17:89-96.
99. Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 2003, 63:7777-7784.